Protective effects of ethyl pyruvate in cisplatin-induced nephrotoxicity

Basit Öğe Kaydı
dc.contributor.authorKelle, Ilker
dc.contributor.authorAkkoc, Hasan
dc.contributor.authorTunik, Selcuk
dc.contributor.authorNergiz, Yusuf
dc.contributor.authorErdinc, Meral
dc.contributor.authorErdinc, Levent
dc.date.accessioned2024-04-24T17:07:44Z
dc.date.available2024-04-24T17:07:44Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractThis study was performed to investigate the effect of ethyl pyruvate on changes in renal functions and oxidative stress related renal injury caused by cisplatin (cis-dichlorodiammine platinum-II; CDDP). Male Wistar albino rats were divided into four groups (n = 8): (1) control group (1ml Ringer's lactate solution i.p.); (2) ethyl pyruvate (EP) group (50mg/kg Ringer's EP solution (REPS) i.p.); (3) cisplatin group (a single dose of cisplatin (5mg/kg, i.p.); and (4) cisplatin + EP group (a single dose of cisplatin (5mg/kg, i.p.) + REPS 50mg/kg/day, i.p.) for five days. At the sixth day, kidneys of rats were mounted to a Langendorff apparatus. Renal perfusion pressures were recorded. Blood samples were taken for serum urea, creatinine, total oxidant status (TOS), total antioxidant status (TAS) and oxidative stres index (OSI) evaluations. Kidney tissues were obtained for malondialdehyde (MDA) analyses and histopathological examination. Perfusion pressures, serum urea, creatinine, TOS, OSI and tissue MDA levels were found significantly higher, whereas TAS was notably lower in cisplatin group. Histopathological examination showed apparent renal paranchymal injury in cisplatin group. In cisplatin + REPS group, perfusion pressures, serum urea, creatinine and tissue MDA levels were decreased. Moreover, EP co-administration provided less inflammatory cell infiltration, tubular dilatation, whereas TOS, TAS and OSI improved significantly versus cisplatin group. These findings show that EP has protective effects against cisplatin nephrotoxicity.en_US
dc.identifier.doi10.1080/13102818.2014.942489
dc.identifier.endpage680en_US
dc.identifier.issn1310-2818
dc.identifier.issn1314-3530
dc.identifier.issue4en_US
dc.identifier.pmid26019553
dc.identifier.scopus2-s2.0-84910091200
dc.identifier.scopusqualityQ3
dc.identifier.startpage674en_US
dc.identifier.urihttps://doi.org/10.1080/13102818.2014.942489
dc.identifier.urihttps://hdl.handle.net/11468/16945
dc.identifier.volume28en_US
dc.identifier.wosWOS:000348934100013
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBiotechnology & Biotechnological Equipment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEthyl Pyruvateen_US
dc.subjectNephrotoxicityen_US
dc.subjectTotal Oxidant Status (Tos)en_US
dc.subjectCisplatinen_US
dc.subjectRaten_US
dc.subjectTotal Antioxidant Status (Tas)en_US
dc.subjectOxidative Stress Index (Osi)en_US
dc.titleProtective effects of ethyl pyruvate in cisplatin-induced nephrotoxicityen_US
dc.titleProtective effects of ethyl pyruvate in cisplatin-induced nephrotoxicity
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu